These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26990746)

  • 1. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
    Mai KT; Busca A; Belanger EC
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
    Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
    Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.
    Edgecombe A; Nguyen BN; Djordjevic B; Belanger EC; Mai KT
    Appl Immunohistochem Mol Morphol; 2012 May; 20(3):264-71. PubMed ID: 22498670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nested and microcystic variants of urothelial carcinoma displaying immunohistochemical features of basal-like urothelial cells: an immunohistochemical and histopathogenetic study.
    Mai KT; Hakim SW; Ball CG; Flood TA; Belanger EC
    Pathol Int; 2014 Aug; 64(8):375-81. PubMed ID: 25143125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M; Kim B; Moon KC
    Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
    Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
    Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
    McKenney JK; Desai S; Cohen C; Amin MB
    Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
    Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
    PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive Papillary Basal-like Urothelial Carcinoma: A Subgroup of Urothelial Carcinomas With Immunohistochemical Features of Basal Urothelial Cells Associated With a High Rate of Recurrence and Progression.
    Mai KT; Ball CG; Belanger EC
    Appl Immunohistochem Mol Morphol; 2016 Sep; 24(8):575-82. PubMed ID: 26574632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
    Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
    Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
    Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
    Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urothelial dysplasia of the bladder: diagnostic features and clinical significance.
    Lopez-Beltran A; Montironi R; Vidal A; Scarpelli M; Cheng L
    Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):121-9. PubMed ID: 24344498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.
    Fichtenbaum EJ; Marsh WL; Zynger DL
    Am J Clin Pathol; 2012 Aug; 138(2):190-7. PubMed ID: 22904129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia.
    Desai S; Lim SD; Jimenez RE; Chun T; Keane TE; McKenney JK; Zavala-Pompa A; Cohen C; Young RH; Amin MB
    Mod Pathol; 2000 Dec; 13(12):1315-23. PubMed ID: 11144928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
    Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
    Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation analysis of nuclear morphology, cytokeratin and Ki-67 expression of urothelial carcinoma cells.
    Shuto M; Warigaya K; Watanabe H; Shimizu M; Fukuda T; Murata S
    Pathol Int; 2013 Jun; 63(6):311-7. PubMed ID: 23782333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.
    Rausch S; Hennenlotter J; Scharpf M; Teepe K; Kühs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
    J Cancer Res Clin Oncol; 2016 May; 142(5):937-47. PubMed ID: 26746655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
    Irwin T; Donlan AW; Owens L; Alvarez R; Vakar-Lopez F; Tretiakova M
    Hum Pathol; 2024 Apr; 146():43-48. PubMed ID: 38593961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of GATA-3 and Cytokeratin 5/6 Immunostains in Separating Condyloma Acuminatum Arising in the Urinary Tract From Non-Invasive Papillary Urothelial Carcinoma.
    Montoya-Cerrillo D; Briski LM; Jorda M; Kryvenko ON
    Int J Surg Pathol; 2022 May; 30(3):260-264. PubMed ID: 34665053
    [No Abstract]   [Full Text] [Related]  

  • 20. Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases.
    Sangoi AR; Falzarano SM; Nicolas M; McKenney JK
    Am J Surg Pathol; 2019 Dec; 43(12):1638-1643. PubMed ID: 31368912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.